InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Browse the full record of transactions filed by Hollander David, Directeur de la R&D. Director active across 2 companies, notably Aerie Pharmaceuticals INC. Aggregated, 4 filings have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €15k. History available since 11 November 2021. The latest transaction was disclosed on 4 February 2025 (U). Regulator: SEC (Form 4). All data is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations
David Hollander is the Chief R&D Officer at Aerie Pharmaceuticals Inc. He oversees the research and development activities of the company, which specializes in the pharmaceutical sector. His role is essential for innovation and the development of new products at Aerie.